Product image of Mirabegrón Teva (Mirabegron) supplied by GNH India

Mirabegrón Teva

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegrón Teva (Mirabegron)

Mirabegron, the active ingredient in Mirabegrón Teva, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adult patients.
GNH India supplies Mirabegrón Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Pharma S.L.U.,

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegrón is indicated for conditions affecting bladder storage function within the overactive bladder disease family.

  • Overactive bladder: increases bladder capacity and reduces urgency episodes.
  • Urinary urgency: lessens the sudden need to void.
  • Urinary frequency: decreases daytime voiding frequency.

How It Works

  • Mirabegrón selectively activates β3‑adrenergic receptors on detrusor smooth muscle, causing relaxation during bladder filling. This relaxation expands functional bladder capacity, diminishes involuntary contractions, and thereby reduces urgency and frequency of urination.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Dry mouth
  • Constipation
  • Hypertension
  • Headache
  • Nasopharyngitis
  • Urinary retention (mild)

Serious or Rare Side Effects

  • Severe urinary retention requiring catheterisation
  • Hypertensive crisis
  • Tachycardia
  • Angioedema
  • Anaphylactic reaction
  • Acute renal impairment

Precautions & Warnings

Before initiating therapy, consider patient‑specific risk factors and monitoring requirements.

  • Cardiovascular assessment: monitor blood pressure regularly.
  • Renal function evaluation: adjust use in severe impairment.
  • Concomitant medication review: avoid strong CYP2D6 inhibitors.
  • Caution in uncontrolled hypertension: assess risk‑benefit.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Mirabegrón may interact with several drug classes; clinical judgement is required.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure.
  • Anticholinergic agents: combined use can heighten risk of urinary retention.
  • Other β3‑adrenergic agonists: additive pharmacologic effect may increase adverse events.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma levels.
  • CYP3A4 inducers (e.g., rifampin): may reduce efficacy.
  • Diuretics: concurrent use may exacerbate hypertension.
  • NSAIDs: may potentiate blood‑pressure elevation.
  • Digoxin: potential alteration of serum concentrations.

Frequently Asked Questions

Mirabegrón Teva is prescribed to manage overactive bladder, including symptoms such as urinary urgency, increased frequency, and urge incontinence in adult patients.

Mirabegron selectively stimulates β3‑adrenergic receptors on the detrusor muscle, causing relaxation during bladder filling. This increases functional bladder capacity and reduces involuntary contractions that cause urgency and frequency.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any concomitant medications.

Safety data in pregnancy and lactation are limited. The product should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

Enquiries can be submitted through the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegrón belongs to a different class (β3‑adrenergic agonist) and works by relaxing bladder muscle rather than blocking muscarinic receptors. It may be preferred when anticholinergics cause dry mouth, constipation, or are contraindicated, but individual response varies.

Store the tablets at temperatures below 25 °C, in the original packaging, and protect them from moisture and direct sunlight to maintain product stability.

Mirabegrón Teva is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional.

Serious risks include severe hypertension, significant urinary retention that may require catheterisation, tachycardia, angioedema, and rare cases of anaphylaxis. Patients should seek immediate medical attention if these events occur.

Patients with uncontrolled hypertension, severe renal impairment, known hypersensitivity to mirabegron, or those taking strong CYP2D6 inhibitors should avoid using Mirabegrón Teva unless a clinician determines the benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT